Gelonghui, March 5th丨Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the revenue from its Business in the USA accounts for a small proportion of the company's overall Business revenue, and the additional tariffs imposed by the USA are expected to have no significant impact on the company's performance.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Southbound funds have seen a historic Inflow again: in the first quarter, over 420 billion Hong Kong dollars were purchased, and Technology stocks are no longer the first choice.
In 2024, SenseTime's adjusted net loss was 4.253 billion yuan, a year-on-year narrowing of 21.5%.
POP MART: The total revenue for the year 2024 is 13.038 billion yuan, a year-on-year increase of 106.9%.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
京新药业(002020.SZ):在美国的业务收入占公司整体业务收入的比例不大
Zhejiang Jingxin Pharmaceutical (002020.SZ): The revenue from the business in the USA accounts for a small proportion of the company's overall business revenue.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 245
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report